Jefferies Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $33
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Jefferies analyst Maury Raycroft maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and lowers the price target from $36 to $33.
Jefferies analyst Maury Raycroft maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and lowers the price target from $36 to $33.